Mixed Findings on GLP-1 Medications and Their Impact on Mental Health

Research into the effects of glucagon-like peptide-1 (GLP-1) medications on mental health yields mixed results, with some studies indicating potential benefits while others suggest increased risks for conditions like depression and anxiety.

Overview of GLP-1 Medications

GLP-1 medications have gained popularity for their role in weight management and diabetes treatment. As prescriptions for these medications rise, particularly among individuals facing obesity or metabolic disorders, concerns about their mental health effects have emerged. GLP-1 receptors are located in brain regions that influence mood and stress response, leading researchers to investigate the medications’ potential psychological implications.

Research Findings on Mental Health

Evidence regarding the mental health effects of GLP-1 medications is varied. A systematic review and meta-analysis published in 2025 examined 80 randomized clinical trials involving adults with overweight, obesity, or diabetes. Findings revealed that participants taking GLP-1 medications experienced improved quality of life and emotional eating behaviors without significant changes in depressive symptoms or psychiatric events. Conversely, a 2024 meta-analysis indicated reduced depressive symptoms in individuals with type 2 diabetes after 24 to 60 weeks on GLP-1 therapy.

However, a cohort study from 2024 raised concerns, noting that among adults with obesity, 39.64% of those on GLP-1 therapy reported psychiatric issues, compared to 23.38% who did not receive the medication.

Implication for Eating Disorders

Some studies suggest that GLP-1 medications could be beneficial for individuals with binge eating disorder. A systematic review published in 2025 highlighted improvements in Binge Eating Scale scores among participants taking GLP-1 medications. However, caution is warranted, as these medications may exacerbate issues related to body image, particularly among those with restrictive eating disorders.

Need for Caution and Further Research

Despite some promising findings, the relationship between GLP-1 medications and mental health remains complex. A 2024 analysis of the FDA Adverse Event Reporting System revealed over 8,240 reports of psychiatric-related events among users since 2004, including symptoms such as anxiety and insomnia. It’s essential for individuals taking these medications to discuss any emerging mental health concerns with their healthcare provider to ensure appropriate management.

THE CNP TAKEAWAY

As research into GLP-1 medications continues, individuals should remain vigilant regarding their mental health. It’s crucial to communicate with healthcare professionals about any mood changes or psychological symptoms experienced while on these medications.

Images courtesy of Shutterstock.

This article was prepared by CNP based on reporting originally published by Healthline. Read the original news article on: healthline.com or find the CNP study summary in the NPRL.